Twenty-five year evolution of medical hormonal therapy for prostate cancer

BJU International

Volumn 103, Issue 2, 2009, Pages 145-146

  Moul, Judd W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DEGARELIX; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

CANCER PATIENT; CANCER RECURRENCE; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HORMONAL THERAPY; HUMAN; METASTASIS; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES;

ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE III AS TOPIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; OLIGOPEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 58149170709     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08271.x     Document Type: Note

References (10)

1. Schally AV, Arimura A, Kastin AJ et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 1971 173 : 1036 8
2. Shally AV, Comaru-Schally AM. Hypothalamus and reproduction gonadotropin releasing hormone and its analogues clinical applications. Mater Med Pol 1980 12 : 3 8
3. Mariani AJ, Glover M, Arita S. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. J Urol 2001 165 : 104 7
4. Crawford ED. Combined androgen blockade. Eur Urol 1996 29 (Suppl. 2 54 61
5. Loblaw DA, Virgo KS, Nam R et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007 25 : 1596 605
6. Moul JW. Contemporary hormonal management of advanced prostate cancer. Oncology 1998 12 : 499 505 discussion 506-8
7. Speight JL, Roach M III. Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol 2005 23 : 8176 85
8. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7
9. Moul JW, Wu H, Sun L et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004 171 : 1141 7
10. McLeod D, Zinner N, Tomera K et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001 58 : 756 61